Business
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":" LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis.\n\n\nThe dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra's website at ir.aldeyra.com.\n\n\nAfter the live webcast, the event will remain archived on Aldeyra’s website for 90 days.\n\n\nAbout Aldeyra\n\n\nAldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of proliferative vitreoretinopathy and retinitis pigmentosa.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20231218552145/en/\n\nInvestor & Media:\nDavid Burke\nTel: (917) 618-2651\[email protected]\n\n\nSource: Aldeyra Therapeutics, Inc.","length":3198,"tagName":"div"}]